ERBB2 and cancer: Specifically, the anti-EGFR antibody cetuximab inhibits EGFR and its downstream ERK activation, which hinders cancer cell proliferation, whereas ERK activation is maintained in HER2-amplified cells, even under cetuximab treatment (Figure 1).